The introduction of nicotinamide as being a nicotine replacement in e-cigarette and smokeless merchandise represents an important regulatory obstacle for that FDA. Nicotinamide does not have nicotinic receptor agonist activity and is understood to work as a sedative at higher dosages6. The promises produced by Nicotine River, ECBlend, together with